PSTPIP1 Activators
PSTPIP1 activators enhance of the functional activity of PSTPIP1-a cytoskeleton-associated adaptor protein implicated in various cellular processes such as cytoskeletal organization and inflammation signaling pathways. These activators exert their influence by targeting specific biochemical pathways that PSTPIP1 is involved in, ultimately increasing its activity. For instance, certain phosphatase inhibitors can indirectly upregulate PSTPIP1's action by preventing dephosphorylation, a modification that typically reduces PSTPIP1's cellular activity. Given that PSTPIP1 is linked with the regulation of the actin cytoskeleton, compounds that stabilize actin polymers may also serve to enhance PSTPIP1 functionality by promoting its association with F-actin, thereby facilitating its role in cytoskeletal rearrangements. Additionally, small molecules that inhibit competing pathways can result in a relative increase in PSTPIP1-mediated signaling. This occurs as a result of the intricate network of signaling cascades where the inhibition of one pathway can lead to the compensatory activation of another, in this case, those directly involving PSTPIP1.
Furthermore, PSTPIP1's involvement in inflammatory signaling suggests that certain inhibitors of inflammatory pathways may indirectly enhance PSTPIP1 activity by relieving negative feedback loops. Such inhibitors could include specific cytokine signaling blockers that, by inhibiting their target, allow for an increase in PSTPIP1-mediated signaling due to reduced competition or suppression. Moreover, agents that modulate ionic concentrations within cells, such as calcium ionophores, could potentially alter PSTPIP1's conformation or interaction with other proteins, thereby modulating its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels, which in turn activates PKA. PKA phosphorylation has been linked to the regulation of the actin cytoskeleton, where PSTPIP1 is known to be involved, enhancing its activity in cytoskeletal reorganization. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can lead to actin cytoskeleton rearrangements. As PSTPIP1 is implicated in actin polymerization, PKC activation may enhance PSTPIP1's role in this process. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium levels, which can activate calcium-dependent kinases that modulate the actin cytoskeleton, enhancing PSTPIP1's function in actin dynamics. | ||||||
Manganese(II) chloride beads | 7773-01-5 | sc-252989 sc-252989A | 100 g 500 g | $19.00 $31.00 | ||
Manganese is a cofactor for kinases and phosphatases. Higher intracellular concentrations can activate these enzymes, potentially enhancing PSTPIP1 activity if it is regulated by such enzymes. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits several tyrosine kinases, which could reduce competitive signaling pathways and indirectly enhance the function of PSTPIP1 in actin remodeling and cellular signaling. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cell-permeable cAMP analog that activates PKA. Enhanced PKA activity can modulate actin dynamics, potentially increasing the activity of PSTPIP1 in the cytoskeleton. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3, which is involved in Wnt signaling. Inhibition of GSK-3 may lead to cytoskeletal rearrangements that could enhance PSTPIP1's functional activity in the cell. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid inhibits farnesyl pyrophosphate synthase, affecting prenylation and localization of small GTPases, which can modulate actin dynamics and potentially enhance PSTPIP1's activity. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
Bay K 8644 is a L-type calcium channel agonist, which increases intracellular calcium, potentially enhancing PSTPIP1 activity through the activation of calcium-dependent pathways involved in the regulation of the actin cytoskeleton | ||||||